Synendos Therapeutics
PrivateLast Round
Grant
Oct 30, 2024
Total Funding Raised
$32.2M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Synendos Therapeutics is a neuroscience company developing therapies for neuropsychiatric and neurological disorders by modulating the endocannabinoid system.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Mental Health
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Synendos Therapeutics Comparables
Compare Synendos Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| H. Lundbeck A/S | 77% | |
| Roche Holding | 71% | |
| Bristol Myers Squibb | 71% |
Synendos Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Oct 30, 2024 | ||||
| Grant | Apr 20, 2021 | ||||
| Series A | Nov 12, 2020 | ||||
| Grant | Oct 1, 2020 | ||||
| Grant | Nov 1, 2019 | ||||
Grant | Aug 1, 2019 |
Key People
Founding team and executive leadership
Synendos Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Gebert Rüf Stiftung | Grant |
| Ysios Capital | Series A, Grant |
| Eurostars SME programme | Grant |
| BERNINA BioInvest AG | Series A |
| Innosuisse | Grant |
| BaseLaunch | Accelerator |
| Sunstone Life Science Ventures | Grant, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 76% MoM.
- Aug 12, 2025
Dr. George Garibaldi appointed as new Chief Medical Officer.
Synendos Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Synendos Therapeutics's valuation, stock price, and market status.
Is Synendos Therapeutics a public or private company?
Synendos Therapeutics is a private company.
What is the current stock price of Synendos Therapeutics?
Synendos Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Synendos Therapeutics worth (valuation)?
Valuation information for Synendos Therapeutics is not publicly available.
Can I buy Synendos Therapeutics stock?
Synendos Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Synendos Therapeutics's last funding round?
Synendos Therapeutics's most recent funding round was Grant on October 30, 2024.
Who are the main investors in Synendos Therapeutics?
Key investors in Synendos Therapeutics include Ysios Capital, Sunstone Life Science Ventures, Kurma Partners.
Will Synendos Therapeutics IPO soon?
No public IPO plans have been announced for Synendos Therapeutics.
How can I track Synendos Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Synendos Therapeutics's secondary market activity and sign up for updates.